Study of the Collaborative Life Skills Program
Not Applicable
Completed
- Conditions
- Attention Deficit Hyperactivity Disorder Symptoms
- Registration Number
- NCT01686724
- Lead Sponsor
- University of California, San Francisco
- Brief Summary
This study tests the effectiveness of a newly developed integrated school-home behavioral intervention for behaviors related to Attention Deficit Hyperactivity Disorder (ADHD). The intervention is implemented by school-based mental health professionals within school settings.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 504
Inclusion Criteria
- Attending a participating school and in 2-5th grade
- Referral by LSP as a child with apparent ADHD-related problems
- ≥ 6 symptoms (item score ≥ 2) of Inattention or Hyperactivity-Impulsivity on the pooled parent and teacher Child Symptom Inventory
- ≥ 3 on the Impairment Rating Scale by parent and teacher (cross-situational impairment)
- FSIQ or VIQ ≥ 80 (necessary for cognitive demands of the child skills curriculum)
- Caretaker consents to participate in treatment, child assents to participate
Exclusion Criteria
- Presence of conditions that are incompatible with this study's treatment.
- severe visual or hearing impairment,
- severe language delay,
- psychosis,
- pervasive developmental disorder
- Parent or child does not read or speak English or does not read or speak Spanish for our Spanish language implementation of CLS (inability to complete assessment measures or participate in group treatments).
- Child is in an all-day special education classroom (children in these classrooms are frequently receiving intensive behavior modification programs such that the intervention would be expected to require modification for use in these settings)
- Children taking psychotropic medication for any reason other than to treat ADHD
- Children planning to change (start or stop) psychotropic medication
- Children who have changed a regimen of psychotropic medication (started or stopped) within 30 days prior to screening
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Symptoms of Attention Deficit Hyperactivity Disorder as defined by DSMIV/V. change from baseline on ADHD symptoms at 12 weeks
- Secondary Outcome Measures
Name Time Method Observations of classroom/school behavior change from baseline in observed on-task behavior at 7 months Academic Achievement change from baseline in academic achievement at 7 months Test of Life Skills Knowledge change from baseline in life skills knowledge at 7 months Alabama Parenting Questionnaire change from baseline in parenting practices at 7 months Children's Organizational Skills Scale (COSS) change from baseline in COSS at 7 months Homework Problems Checklist (HPC) change from baseline in homework problems at 7 months Academic Competency Evaluation Scale (ACES) change from baseline in ACES at 7 months Academic achievement change from baseline in academic achievement at 12 weeks Parenting Stress Index change from baseline in parenting stress at 7 months Social Skills Improvement Scale change from baseline in social/behavioral functioning at 7 months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does the Collaborative Life Skills Program (CLS) in NCT01686724 modulate ADHD-related neural pathways compared to methylphenidate?
What is the comparative efficacy of CLS (NCT01686724) versus standard-of-care stimulant therapy for ADHD symptom management in school settings?
Which neurobiological biomarkers predict response to the Collaborative Life Skills Program (CLS) in NCT01686724 for ADHD subtypes?
What implementation challenges and management strategies were observed in NCT01686724's school-based CLS intervention for ADHD?
How does the Collaborative Life Skills Program (CLS) in NCT01686724 synergize with pharmacotherapy for ADHD in integrated treatment models?
Trial Locations
- Locations (1)
University of California San Francisco
🇺🇸San Francisco, California, United States
University of California San Francisco🇺🇸San Francisco, California, United States